Boston — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments. “2022...
Latest News
IRVINE, Calif. — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached...
New Delhi – Achalasia is a disease where the function of the oesophagus stops working overtime. It is thought to be neural degeneration of the selective nerve fibers in the body of the oesophagus and the valve at the top of the stomach. It is a rare disease with an...
TUSTIN, Calif. — Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body’s own immune system...
Peregrine has presented the data for ongoing trail for brain cancer at Society of Nuclear Medicine 2009 Annual Meeting. The study supports the potential for Cotara to treat brain cancer. Cotara, a targeted monoclonal antibody linked to a radioisotope, is being developed as a potential new treatment for glioblastoma multiforme...
Reston, VA — PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in the April issue of The Journal of Nuclear Medicine. By applying the PRIMARY scoring system to PET/MRI results, researchers found that more than 80 percent of unnecessary biopsies...
NEW YORK & MIAMI – Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for...
NEW YORK, NY — Pfizer Inc.(NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival...
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks. Both boards have approved the transaction, which is expected to close in...
New York, NY – The novel hemophilia therapeutic marstacimab has been accepted for submission by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for regulatory approval, according to a news release. Pfizer announced in a news release that the Biologics License Application (BLA) for its...